A buyout resolves the funding forward for maximum efficacy, though, versus a rs delays forward progress, and there is more upside to quickly going forward than a rs could offer given these drugs combined easily represent billions in profit sooner than later?
Or are a rs and a buyout comparable in their Tyractiveness to a BP buyer?
Yeah but the only problem with a immediate buyout is shareholders may not feel impact of hitting milestones and the huge market cap increase that comes as drugs are closer to market…
If a cash payment to acquire the drug platform was plenty sufficient, there would be plenty of money to eliminate any further debt and dilution and excess cash could be utilized to further other platforms while listing higher exchange could bring institutional support while waiting for milestones and chunk payments to come in.
All speculation but that is the fun of the OTC. Would love to hear status update and forward plans from the company….
News 
Market Data 
Discover 
AI
